Literature DB >> 17273928

Guanidinoacetate inhibits glutamate uptake in rat striatum of rats at different ages.

Alexandra I Zugno1, Diogo L Oliveira, Emilene B S Scherer, Moacir Wajner, Susana Wofchuk, Angela T S Wyse.   

Abstract

Glutamate plays a central role in the excitatory synaptic transmission and is important for brain development and functioning. Increased glutamate levels in the synaptic cleft are related to neuronal damage associated with excitotoxicity. Guanidinoacetate methyltransferase (GAMT) deficiency is an inherited neurometabolic disorder biochemically characterized by tissue accumulation of guanidinoacetate (GAA) and depletion of creatine. Affected patients present epilepsy and mental retardation whose pathogeny is unclear. In the present study we investigated the in vitro and in vivo (intrastriatal administration) effect of GAA on glutamate uptake by striatum slices of developing and adult rats. Results showed that GAA significantly inhibited in vitro glutamate uptake at 50 microM and 100 microM in all ages tested. We also tested the effect of taurine on the inhibition of glutamate uptake caused by GAA. Taurine significantly attenuated the inhibitory effect caused by 50 microM GAA, but did not alter that provoked by 100 microM GAA. Furthermore, intrastriatal administration of a solution of 30 microM GAA (0.06 nmol/striatum) significantly inhibited glutamate uptake by rat striatum slices. Our results suggest that the inhibition of striatal glutamate uptake caused by GAA might be involved in the neuropathology and especially in the acute neurological features present in patients with GAMT-deficiency.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17273928     DOI: 10.1007/s11064-006-9245-1

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   4.414


  32 in total

Review 1.  Apoptosis and caspases in neurodegenerative diseases.

Authors:  Robert M Friedlander
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

2.  The role of taurine and glutamate during early postnatal cerebellar development of normal and weaver mutant mice.

Authors:  E Trenkner
Journal:  Adv Exp Med Biol       Date:  1990       Impact factor: 2.622

3.  Intrastriatal administration of guanidinoacetate inhibits Na+, K+-ATPase and creatine kinase activities in rat striatum.

Authors:  Alexandra I Zugno; Emilene B S Scherer; Patrícia F Schuck; Diogo L Oliveira; Suzana Wofchuk; Clovis M D Wannmacher; Moacir Wajner; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2006-04-27       Impact factor: 3.584

4.  Guanidino compounds generate reactive oxygen species.

Authors:  A Mori; M Kohno; T Masumizu; Y Noda; L Packer
Journal:  Biochem Mol Biol Int       Date:  1996-09

5.  Non-vesicular release of glutamate from glial cells by reversed electrogenic glutamate uptake.

Authors:  M Szatkowski; B Barbour; D Attwell
Journal:  Nature       Date:  1990-11-29       Impact factor: 49.962

6.  Attenuation of seizures induced by homocysteic acid in immature rats by metabotropic glutamate group II and group III receptor agonists.

Authors:  J Folbergrová; R Haugvicová; P Mares
Journal:  Brain Res       Date:  2001-07-27       Impact factor: 3.252

Review 7.  Taurine and neural cell damage.

Authors:  P Saransaari; S S Oja
Journal:  Amino Acids       Date:  2000       Impact factor: 3.520

Review 8.  Taurine as a universal carrier of lipid soluble vitamins: a hypothesis.

Authors:  A M Petrosian; J E Haroutounian
Journal:  Amino Acids       Date:  2000       Impact factor: 3.520

Review 9.  Taurine analogues; a new class of therapeutics: retrospect and prospects.

Authors:  R C Gupta; T Win; S Bittner
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

Review 10.  Glutamatergic neurotransmission in aging: a critical perspective.

Authors:  G Segovia; A Porras; A Del Arco; F Mora
Journal:  Mech Ageing Dev       Date:  2001-01       Impact factor: 5.432

View more
  7 in total

1.  Cellular changes underlying hyperoxia-induced delay of white matter development.

Authors:  Thomas Schmitz; Jonathan Ritter; Susanne Mueller; Ursula Felderhoff-Mueser; Li-Jin Chew; Vittorio Gallo
Journal:  J Neurosci       Date:  2011-03-16       Impact factor: 6.167

Review 2.  Guanidinoacetic Acid as a Nutritional Adjuvant to Multiple Sclerosis Therapy.

Authors:  Sergej M Ostojic
Journal:  Front Hum Neurosci       Date:  2022-05-12       Impact factor: 3.473

3.  Guanidino acids act as rho1 GABA(C) receptor antagonists.

Authors:  Mary Chebib; Navnath Gavande; Kit Yee Wong; Anna Park; Isabella Premoli; Kenneth N Mewett; Robin D Allan; Rujee K Duke; Graham A R Johnston; Jane R Hanrahan
Journal:  Neurochem Res       Date:  2009-04-23       Impact factor: 3.996

4.  Guanidinoacetate administration increases acetylcholinesterase activity in striatum of rats and impairs retention of an inhibitory avoidance task.

Authors:  Alexandra I Zugno; Lenir O Pereira; Cristiane Mattos; Emilene B S Scherer; Carlos A Netto; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2008-04-24       Impact factor: 3.584

5.  Effects in vitro of guanidinoacetate on adenine nucleotide hydrolysis and acetylcholinesterase activity in tissues from adult rats.

Authors:  Roselia Maria Spanevello; Angela Terezinha de Souza Wyse; Cinthia Melazzo Mazzanti; Roberta Schmatz; Naiara Stefanello; Jamile Fabbrin Gonçalves; Margarete Bagatini; Vanessa Battisti; Vera Maria Morsch; Maria Rosa Chitolina Schetinger
Journal:  Neurochem Res       Date:  2008-02-07       Impact factor: 3.996

Review 6.  Safety of Dietary Guanidinoacetic Acid: A Villain of a Good Guy?

Authors:  Sergej M Ostojic
Journal:  Nutrients       Date:  2021-12-24       Impact factor: 5.717

Review 7.  Effects of Creatine Supplementation on Brain Function and Health.

Authors:  Scott C Forbes; Dean M Cordingley; Stephen M Cornish; Bruno Gualano; Hamilton Roschel; Sergej M Ostojic; Eric S Rawson; Brian D Roy; Konstantinos Prokopidis; Panagiotis Giannos; Darren G Candow
Journal:  Nutrients       Date:  2022-02-22       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.